Business Wire

Synack Commits to Supporting the Advancement of Women in Cybersecurity by Launching a Courageous Women in Security Initiative

5.8.2019 19:00:00 EEST | Business Wire | Press release

Share

New York Times reporter Jessica Bennett observed that the 2020 female Democratic candidates have largely avoided the phrase “glass ceiling”, prompting linguist Robin Lakoff to speculate that the phrase just “seems tired”. On the debate floor, action-oriented and empowering words like “persist” are replacing phrases like “glass ceiling” and the “stuck-ness” implicitly suggested by them. It’s not just in politics that women are intentionally working toward changing society’s perception of them in the workplace; it’s happening in cybersecurity too.

Today, women make up only 20% of the cybersecurity industry’s workforce. This largely untapped demographic could be the saving grace for an industry desperate for skilled labor and on pace to hit 3.5 million unfilled jobs by 2021 according to Cybersecurity Ventures. This is why today Synack launches their “Courageous Women CISO Initiative” which aims to encourage more women to enter the cybersecurity field; offer support by creating a strong network for women; and provide a platform for women to share their voice in the boardroom, across the aisles in policy, and from the podium at leading industry conferences. Synack will build upon efforts that aim to close the talent gap in other ways (like encouraging young women to enter into STEM fields) by empowering women to get to the forefront of cybersecurity innovation and lead the charge in making our organizations more secure. The company is also encouraging more women to apply to their elite Synack Red Team, the world’s best and most trusted crowd of ethical hackers.

“When the concept of harnessing a crowd of ethical hackers was novel, Synack found that women CISOs were 2x more likely to adopt crowdsourced security, which showed that female security leaders are willing to be bold and courageous when facing decisions that can make their organizations more secure. Cybersecurity is a field that needs more diversity in thought and action, and women are an underrepresented group. We need more female leaders in the field who have successfully navigated the industry to be examples and mentors to newcomers,” said Aisling MacRunnels, Synack CMO and Courageous Women CISO Initiative Chair.

Synack’s initiative aims to connect and empower security’s female change-makers through a series of networking events and opportunities to speak from the podium at industry-renowned conferences. Synack has partnered with Microsoft/M12, CyberWire and now Booz Allen Hamilton to host popular women’s networking events at Black Hat USA, RSA Conference, and Billington Cybersecurity Summit; later this week, the company will host their 3rd annual Women’s Brunch at Black Hat USA. Through these efforts, Synack aims to …

  • Close the talent gap in cybersecurity by increasing the number of women entering the industry by 50% by 2022.
  • Increase the number of women speaking at industry conferences, so that the percentage of female speakers is on par with the percentage of male speakers by 2022.

After the women’s lunch at the RSA Conference 2019, partners M12 and CyberWire said, “We had a great time with the Synack team today - if only every lunch could be filled with so many impressive women! A big thank you to our amazing hosts: Lisa Nelson, Microsoft Ventures and Aisling MacRunnels, Synack,” (M12), and “It is our pleasure to support and empower women in the field of cybersecurity!” (Cyberwire).

Synack’s Courageous Women CISO initiative was developed to bring female security leaders and executives together to support each other in having a bigger impact in their companies and industry. Through this initiative, Synack’s goal is to create an environment that fosters authentic conversations and provides a support network for women in cybersecurity. Let’s change the status quo in cybersecurity together - RSVP for upcoming events for women and learn more about Synack’s Courageous Women CISO Initiative here: https://go.synack.com/courageous-women-ciso.html.

About Synack

Synack, the most trusted crowdsourced security platform, delivers continuous and scalable penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create an efficient and effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ellie McCardwell, Synack Communications
press@synack.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye